Table 2. Cross-reactivity of insulin analogues in the Lumipulse G1200 and Roche E170 systems.
Concentration (pmol/L) | Detection level (cross-reactivity %) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Humulin | Insulin lispro | Insulin detemir | Insulin aspart | Insulin glulisine | Insulin glargine | |||||||
G1200 | E170 | G1200 | E170 | G1200 | E170 | G1200 | E170 | G1200 | E170 | G1200 | E170 | |
6,940 | > 100% | > 100% | < 0.1% | < 0.2% | < 0.1% | < 0.2% | 0.16% | < 0.2% | 0.28% | 0.32% | 9.3% | < 0.2% |
694 | > 100% | > 100% | < 0.1% | < 0.2% | < 0.1% | < 0.2% | < 0.1% | < 0.2% | 1.4% | 2.6% | 6.3% | < 0.2% |
69.4 | > 100% | > 100% | < 0.1% | < 0.2% | < 0.1% | < 0.2% | < 0.1% | < 0.2% | 0.3% | 1.1% | 2.0% | < 0.2% |
6.94 | > 100% | > 100% | < 0.1% | < 0.2% | < 0.1% | < 0.2% | < 0.1% | < 0.2% | < 0.1% | < 0.2% | < 0.1% | < 0.2% |